Faes Farma’s strong performance in H1 18, was attributable to the consolidation of Diafarm, ITF, and Technovit, along with continuous uptake in the Bilastine (globally) and strong performance of new molecules (especially Hidrofrel). However, generic pressure on mature portfolio and subdued performance of ITF+Technovit remain a short-term concern. Patent expiry of the star drug, Bilastine, in 2022, will be a cause of concern in mid to long-term.
28 Aug 2018
Strong revenue growth complemented by improved margins
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong revenue growth complemented by improved margins
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
28 Aug 2018 -
Author:
Kamla Singh -
Pages:
3
Faes Farma’s strong performance in H1 18, was attributable to the consolidation of Diafarm, ITF, and Technovit, along with continuous uptake in the Bilastine (globally) and strong performance of new molecules (especially Hidrofrel). However, generic pressure on mature portfolio and subdued performance of ITF+Technovit remain a short-term concern. Patent expiry of the star drug, Bilastine, in 2022, will be a cause of concern in mid to long-term.